

## Research Article

# Evaluation of the Prognostic Value of Solute Carrier Family 34 Member 2 “SLC34A2” in Papillary Thyroid Carcinoma: An Immunohistochemical Study

Sarah Adel Hakim <sup>1</sup>, Rasha Mohamed Abd El Atti <sup>1</sup>, Reham Mohamed Faheim <sup>2</sup>,  
and Hoda Hassan Abou Gabal <sup>1</sup>

<sup>1</sup>Assistant Professors of Pathology, Faculty of Medicine, Ain Shams University, Egypt

<sup>2</sup>Lecturer of Clinical Oncology, Faculty of Medicine, Ain Shams University, Egypt

Correspondence should be addressed to Sarah Adel Hakim; sarahadel2003@yahoo.com

Received 26 May 2021; Revised 29 June 2021; Accepted 5 July 2021; Published 15 July 2021

Academic Editor: Giovanni Tuccari

Copyright © 2021 Sarah Adel Hakim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Background.** Papillary thyroid carcinoma (PTC) usually has an indolent clinical course, yet a subset of patients might show an aggressive course. Thus, better stratification of at-risk patients is mandatory for proper management. Solute carrier family 34 member 2 (SLC34A2) is an independent prognostic indicator in several cancers. However, only a few studies have been conducted to evaluate the prognostic value of SLC34A2 in PTC, with none of them assessing its immunohistochemical (IHC) expression in a large cohort of patients with PTC or exploring its possible relationship with tumor progression. **Aim of the Study.** We aimed to evaluate the IHC expression of SLC34A2 in a large series of PTC patients, correlate its expression with established clinicopathological factors, and find any possible relationship between this marker and patient prognosis. **Material and Methods.** A total of 476 samples (including 238 samples of PTC and 238 samples of normal thyroid tissue) collected between 2002 and 2005 were extracted from the archives of the Pathology Lab, Ain Shams University Hospitals. IHC analysis was performed using an anti-SLC34A2 antibody. Follow-up data were obtained. **Results.** High SLC34A2 expression significantly correlated with important adverse clinicopathological parameters of PTC—i.e., late tumor stage, positive extrathyroid extension, tumor size > 4 cm, and age ≥ 55 years ( $p \leq 0.001$  for each). Kaplan–Meier analysis revealed that high SLC34A2 expression significantly correlated with shorter disease-free survival (DFS;  $p = 0.005$ ), but not with overall survival ( $p = 0.111$ ). Multivariate analysis showed SLC34A2 to be an independent prognostic factor affecting DFS. **Conclusions.** High SLC34A2 IHC expression correlated with adverse clinicopathological prognostic parameters. Furthermore, SLC34A2 was identified as an independent factor for DFS that could serve to improve risk stratification of PTC patients for better management.

## 1. Introduction

Papillary thyroid carcinoma (PTC) is the most commonly encountered subtype of thyroid cancer, with increased incidence in recent decades [1–3]. Although it generally shows an indolent clinical course, there are patients with aggressive PTC at presentation who are most likely to develop local recurrences and distant metastases with unfavorable outcomes. Therefore, identifying this subset of patients becomes a top priority for the proper management of PTC, highlight-

ing the importance of finding efficient prognostic biomarkers and new therapeutic targets in this context [4, 5].

Solute carrier family 34 member A2 (SLC34A2) is the most recognized member of solute carrier family 34. It is a sodium-dependent phosphate transporter that imports phosphate into cells, including tumor cells. Inorganic phosphate is crucial for different cell functions. SLC34A2 has a dual nature, acting as both a tumor suppressor and a tumor promoter in a context-dependent manner and therefore exhibiting upregulation in some tumors and downregulation in others [5–7].

Only a few studies have examined the SLC34A2 gene in PTC by real-time polymerase chain reaction or alternative techniques, demonstrating increased SLC34A2 gene expression in PTC [5, 8, 9]. No immunohistochemical (IHC) studies have been conducted on large cohorts to evaluate SLC34A2 expression in PTC. Moreover, none of the previous studies has assessed the possible role of SLC34A2 on tumor progression. Thus, the current study was aimed to evaluate the IHC expression of SLC34A2 in a large series of patients with PTC, correlate its expression with established clinicopathological prognostic parameters of PTC, and find any possible relationship between this marker and patient prognosis.

## 2. Material and Methods

**2.1. Tissue and Patient Data.** A total of 476 samples (including 238 samples of PTC and 238 samples of normal thyroid tissue) collected between 2002 and 2005 were extracted from the archives of the Pathology Lab, Ain Shams University Hospitals. Only cases with enough tissue were included in the analysis. Hematoxylin and eosin-stained slides were examined to evaluate and verify the histopathologic diagnosis. Follow-up data were obtained from the archives of Clinical Oncology Department to determine (a) overall survival time (OS), which was calculated from the date of diagnosis until the date of last follow-up or death, and (b) disease-free survival (DFS), which was calculated from the date of surgery to the date of progression (local recurrence or distant metastasis).

**2.2. Ethics Statement.** All patients who participated in this study signed written informed consent before surgery. The study was approved by the Research Ethical Committee at the Faculty of Medicine, Ain Shams University.

**2.3. IHC Staining.** Four-micrometer sections of formalin-fixed and paraffin-embedded samples of PTC and normal thyroid tissue were prepared for IHC staining with primary antibodies, e.g., rabbit monoclonal anti-SLC34A2 antibody (clone: SP322 N-terminal (ab228474); ABCAM, MA, USA; 1:100 dilution). Next, the avidin-biotin immunoperoxidase complex technique was employed as described by Hsu et al. [10] by means of a sensitive detection kit (Biogenex, CA, USA). The tissue sections were then subjected to a fixation on poly-L-lysine-coated slides overnight at 37°C, followed by deparaffinization and rehydration. After antigen retrieval in a microwave oven in 10 mM citrate buffer (pH 6.0) for 20 min, endogenous peroxidase activity was blocked using 3% hydrogen peroxide, and the sections were treated with Protein Block Serum-Free Solution (Dako Cytomation, Glostrup, Denmark) for 20 min and were subsequently incubated overnight at 4°C with primary antibodies. Afterward, biotinylated anti-mouse immunoglobulin and streptavidin conjugated to horseradish peroxidase were applied, and 3,3'-diaminobenzidine was used as a chromogen substrate to form an insoluble brown product. Finally, the sections were counterstained with hematoxylin and permanently mounted. With each run, sections of lung adenocarcinoma were used as positive controls for SLC34A2 [11]. Negative control sections

TABLE 1: Clinicopathological characteristics of PTC cases.

(a)			
	Mean	±SD (range)	
Age	43.62	12.77 (18.00–86.00)	
Tumor size (cm)	3.78	1.27 (1.00–7.00)	
(b)			
		Number	%
Age group	<55	122	51.3%
	≥55	116	48.7%
Gender	Male	48	20.2%
	Female	190	79.8%
Lymph node involvement at presentation	N0	164	68.9%
	N1	74	31.1%
Lymphovascular invasion	Negative	192	80.7%
	Positive	46	19.3%
Capsular invasion	Negative	127	53.4%
	Positive	111	46.6%
PTC variants	Classic	172	72.3%
	Follicular	51	21.4%
	Other	15	6.3%
Extrathyroid extension	Negative	207	87.0%
	Positive	31	13.0%
Stage	I	189	79.4%
	II	38	16.0%
	III	11	4.6%
Tumor size (cm)	≤4	114	47.9%
	>4	124	52.1%
Distant metastasis	Negative	219	92.0%
	Positive	19	8.0%
Local recurrence	Negative	205	86.1%
	Positive	33	13.9%
Outcome	Dead	16	6.7%
	Alive	222	93.3%

were incubated with normal mouse serum instead of the primary antibody.

**2.4. Interpretation of IHC Staining.** Positive SLC34A2 IHC staining was detected in the membrane of tumor cells. SLC34A2 IHC expression was scored according to the percentage of positively stained tumor cells (0, <10%; 1, 10%–40%; 2, 40%–70%; and 3, >70%) and the intensity of staining (0, negative; 1, yellowish; 2, light brown; and 3, dark brown). A final immunoreactivity score was obtained for each case by multiplying the percentage of stained cells score by the intensity score (0–9) [5, 12, 13]. IHC analysis of SLC34A2 was blindly performed by 3 pathologists without




FIGURE 1: Normal thyroid tissue (control): showing low SLC34A2 IHC expression (IHCX100) (a), PTC with adjacent normal thyroid tissue: (H&E) (b), and PTC showing high SLC34A2 IHC expression in contrast with low SLC34A2 IHC expression in adjacent normal thyroid tissue (IHCX100) (c).

any prior knowledge of the clinicopathological data. Any discrepancy between the 3 pathologists was resolved using a multihead microscope to reach a consensus.

Immunoreactivity for SLC34A2 was classified into 2 groups, namely, low expression (final score < 6) and high expression (final score  $\geq$  6) [5].

### 3. Data Management and Analysis

Continuous variables were expressed as mean  $\pm$  standard deviation, and categorical variables were reported as frequencies and percentages. Student's *t*-test was used to assess the statistical significance of differences between the 2 study groups. The chi-square test and Fisher's exact test were used to examine the relationship between categorical variables. OS and DFS were determined using Kaplan–Meier curves and compared by the log-rank test. We used a backward Cox regression model to compare time to specified events, taking into consideration the values of significant variables in univariate analysis. A significance level of  $p < 0.05$  was used in all tests. All statistical procedures were carried out using SPSS version 20 for Windows (SPSS Inc., Chicago, IL, USA).

### 4. Results

A total of 238 cases of PTC were included in the current study, of whom 48 were males (20.2%) and 190 were females (79.8%). The mean age was  $43.62 \pm 12.77$  years (range, 18–86 years). PTC variants were found to be classic ( $n = 172$ ), follic-

ular ( $n = 51$ ), tall cell ( $n = 10$ ), and solid ( $n = 5$ ). Detailed clinicopathological characteristics are presented in Table 1.

Papillary thyroid carcinoma (PTC); standard deviation (SD).

**4.1. IHC Analysis.** All control samples of normal thyroid tissue ( $n = 238$ ), as well as normal thyroid tissue adjacent to the tumor, showed low SLC34A2 IHC expression (Figure 1). On the other hand, a significant elevation of SLC34A2 expression was detected in 68.5% of PTC cases, with high membranous SLC34A2 expression observed in 163 out of 238 PTC cases (Figure 2).

**4.2. Correlation between SLC34A2 Expression and Clinicopathological Parameters.** High SLC34A2 expression was found to be highly significantly associated with advanced tumor stage, positive capsular invasion, positive extrathyroid extension, large tumor size (>4 cm), and age  $\geq$  55 years ( $p \leq 0.001$  for each). However, there was no statistically significant relationship between SLC34A2 IHC expression and PTC histopathological variants ( $p = 0.988$ ), lymph node status at presentation ( $p = 0.484$ ), and lymphovascular invasion ( $p = 0.595$ ) (Table 2).

**4.3. Survival Analysis.** The OS of all PTC cases included in this study was 91.7% at both 10 and 15 years, while their 10- and 15-year DFS turned out to be 74.7% and 68.5%, respectively (Figure 3).




FIGURE 2: Continued.




FIGURE 2: Papillary thyroid carcinoma (PTC) cases. Classic variant of PTC (H&EX100) (a). A case of classic PTC showing high SLC34A2 IHC expression (IHCX100) (b). Another case of classic PTC showing low SLC34A2 IHC expression (IHCX200) (c). Follicular variant of PTC (H&EX200) (d). A case of follicular variant of PTC showing high SLC34A2 IHC expression (IHCX200) (e). Another case of follicular variant of PTC showing low SLC34A2 IHC expression (IHCX200) (f). Tall cell variant of PTC (H&EX200) (g). A case of tall cell variant of PTC showing high SLC34A2 IHC expression (IHCX200) (h). Another case of tall cell variant of PTC showing low SLC34A2 IHC expression (IHCX200) (i). Solid variant of PTC (H&EX100) (j). A case of solid variant of PTC showing high SLC34A2 IHC expression (IHCX200) (k). Another case of solid variant of PTC showing low SLC34A2 IHC expression (IHCX100) (l).

OS at 175 months was 89.3% for PTC cases with high SLC34A2 expression vs. 98.6% for those with low SLC34A2 expression ( $p = 0.111$ ), suggesting there was no statistically significant relationship between SLC34A2 IHC expression and OS. On the contrary, cases with high SLC34A2 IHC expression had significantly shorter DFS at 160 months than those with low SLC34A2 expression (68.4% vs. 94.8%, respectively;  $p = 0.005$ ) (Figure 4).

After adjustment for significant factors affecting OS (i.e., age group, lymph node involvement at presentation, extra-thyroid extension, tumor stage, tumor size, and SLC34A2 IHC expression) by backward Cox regression analysis, lymph node involvement at presentation and tumor stage were identified as independent factors affecting OS (Table 3). By contrast, SLC34A2 IHC expression was not found as an independent factor affecting OS.

After adjustment for significant factors affecting DFS (i.e., age group, lymph node involvement at presentation, capsular invasion, extra-thyroid extension, tumor stage, tumor size, and SLC34A2 IHC expression) by backward Cox regression analysis, lymph node status at presentation, SLC34A2 IHC expression, and age were identified as independent factors affecting DFS (Table 4).

## 5. Discussion

Proper management of PTC requires better stratification of patients so that those with potentially aggressive outcomes can be promptly identified. Therefore, searching for new prognostic biomarkers and therapeutic modalities is essential for improving the prognosis of PTC. SLC34A2 is among the genes that have previously been linked to PTCs associated with the BRAF mutation. Previous studies have shown elevated SLC34A2 gene expression in PTC patients associated with BRAF<sup>v600E</sup> mutations [8, 14]. Moreover, another study has even demonstrated that the SLC34A2 gene is downregulated in BRAF wild-type PTCs [15].

In the current study, a low level of SLC34A2 IHC expression was detected in all normal thyroid tissue samples, whereas there was a sharp rise in the IHC expression of SLC34A2 among PTC cases, with 68.5% of them displaying high SLC34A2 membranous expression. In this context, the only study investigating the IHC expression of SLC34A2 in PTC [5] found similar results, showing SLC34A2 IHC expression was significantly increased among PTC cases (64.4%) compared with normal thyroid tissue. The slight discrepancy in the percentage of expression might be attributed

TABLE 2: Relationship between SLC34A2 IHC expression and clinicopathological characteristics.

		SLC34A2				p value	Significance
		Low		High			
Age group	<55	56	45.9%	66	54.1%	$\leq 0.001^*$	HS
	$\geq 55$	19	16.4%	97	83.6%		
Gender	Male	8	16.7%	40	83.3%	0.013*	S
	Female	67	35.3%	123	64.7%		
Lymph node at presentation	N0	54	32.9%	110	67.1%	0.484 <sup>‡</sup>	NS
	N1	21	28.4%	53	71.6%		
Lymphovascular invasion	Negative	59	30.7%	133	69.3%	0.595 <sup>‡</sup>	NS
	Positive	16	34.8%	30	65.2%		
Capsular invasion	Negative	69	54.3%	58	45.7%	$\leq 0.001^*$	HS
	Positive	6	5.4%	105	94.6%		
PTC variants	Classic	54	31.4%	118	68.6%	0.988*	NS
	Follicular	16	31.4%	35	68.6%		
	Other	5	33.3%	10	66.7%		
Extrathyroid extension	Negative	74	35.7%	133	64.3%	$\leq 0.001^*$	HS
	Positive	1	3.2%	30	96.8%		
Stage	I	72	38.1%	117	61.9%	$\leq 0.001^*$	HS
	II	3	7.9%	35	92.1%		
	III	0	0.0%	11	100.0%		
Tumor size (cm)	$\leq 4$	62	54.4%	52	45.6%	$\leq 0.001^*$	HS
	$>4$	13	10.5%	111	89.5%		

<sup>‡</sup>Student's *t*-test. \*Chi-square test. Solute carrier family 34 member A2 (SLC34A2); immunohistochemical (IHC); papillary thyroid carcinoma (PTC); highly significant (HS); significant (S); not significant (NS).




FIGURE 3: Kaplan Meier analysis of all PTC cases: overall survival (OS) (a) and disease-free survival (DFS) (b).

to their smaller sample size compared to ours. It is known that SLC34A2 might possess oncogenic or tumor-suppressive capabilities, therefore displaying different patterns of expression depending on cancer type [5]. In our study, the IHC expression of SLC34A2 increased in PTC samples as compared to normal thyroid tissue, which is similar to the expression pattern observed in ovarian cancer

[16], breast cancer [17, 18], and osteosarcoma [19]. Nevertheless, SLC34A2 has been reported to be downregulated in some other cancer types, namely, renal cell carcinoma and nonsmall cell lung cancer [20, 21].

The present work revealed that higher SLC34A2 IHC expression was associated with poorer prognostic indicators of PTC, including older age, late tumor stage, larger tumor




FIGURE 4: Kaplan Meier analysis of SLC34A2 IHC expression: correlation with OS is not significant ( $p = 0.111$ ) (a) and high SLC34A2 correlates with shorter DFS ( $p = 0.005$ ) (b).

TABLE 3: Backward Cox regression analysis of important factors affecting OS.

	Hazard ratio (HR)	$p$ value	Significance	95.0% confidence interval for HR	
				Lower	Upper
Lymph node at presentation	8.623	$\leq 0.001$	HS	2.355	31.570
Tumor stage II/III*	4.398	$\leq 0.001$	HS	2.220	8.711

\*Reference Tumor Stage I. Overall Survival (OS); Highly Significant (HS).

TABLE 4: Backward Cox regression analysis of important factors affecting DFS.

	Hazard ratio (HR)	$p$ value	Significance	95.0% CI for HR	
				Lower	Upper
LN at presentation	10.404	$\leq 0.001$	HS	5.023	21.549
High SLC34A2*	3.961	0.025	S	1.186	13.226
Age group $\geq 55$ **	2.775	0.017	S	1.196	6.436

\*Reference low SLC34A2. \*\*Reference age group  $< 55$  years. Disease-free survival (DFS); lymph node (LN); confidence interval (CI); highly significant (HS); significant (S).

size, positive extrathyroidal extension, and positive capsular invasion ( $p \leq 0.001$  for each). In the same vein, several studies exploring SLC34A2 expression in other cancers have revealed a correlation between this marker and different clinicopathological parameters [18, 22]. In bladder cancer, for instance, SLC34A2 expression correlated with advanced tumor stage and large tumor size [23]. On the other hand, in the current work, high SLC34A2 IHC expression was not significantly associated with lymph node status at presentation and lymphovascular invasion ( $p = 0.484$  and  $0.595$ , respectively). These results are not in line with those reported by He et al. [5], who demonstrated that high SLC34A2 IHC expression was only associated with lymph node metastasis at presentation. This discrepancy might be attributed to the small number of PTC patients ( $n = 76$ ) analyzed immunohistochemically in their study, where 36 out of 76 PTC cases (47.36%) pre-

sented with lymph node metastasis. It is worth noting that in our study, only 74 out of 238 PTC cases (31.1%) presented with lymph node metastasis, which is within the established international range of lymph node metastases at presentation in PTC cases (i.e., 30%–40% of PTC cases) [24]. Interestingly, SLC34A2 IHC expression did not correlate with PTC variants ( $p = 0.988$ ), which might indicate a potential prognostic role for SLC34A2 in all PTC variants. This is unlike BRAF<sup>V600E</sup>, which showed less expression in the follicular variant of PTC [25]. This discrepancy between SLC34A2 and BRAF<sup>V600E</sup> suggests that SLC34A2 could be linked to alternative molecular pathways that are yet to be explored.

Our results demonstrated that stage I tumors had a significantly lower level of SLC34A2 expression than did stage III tumors (61.9% vs. 100%, respectively;  $p \leq 0.001$ ). Similar significant differences in the expression of SLC34A2 existed

between PTCs without extrathyroidal extension and those with extrathyroidal extension (64.3% vs. 96.8%, respectively;  $p \leq 0.001$ ), which might have resulted from the fact that SLC34A2 is presumably linked to PTCs associated with the BRAF mutation; hence, a possible explanation for the correlation between SLC34A2 and PTC invasiveness could be the ability of BRAF mutations to induce matrix remodeling genes [25].

In this study, SLC34A2 IHC expression was found to be correlated with gender ( $p = 0.013$ ), with 123 out of 190 females exhibiting high SLC34A2 expression. The effect of gender on PTC prognosis has remained controversial. On the one hand, some studies have revealed that there is no difference between genders concerning disease-specific survival [26], and that male gender is not an independent prognostic factor for cancer-specific survival in PTC [27–29]; on the other hand, several more recent studies have demonstrated that male gender is an independent poor prognostic factor for PTC [30, 31]. Nonetheless, a subgroup analysis revealed that this might be altered by the effect of age and menopause-associated hormonal changes in older females [32], which could explain our current results since most of our cases were older females.

In the present study, Kaplan–Meier analysis demonstrated that high SLC34A2 expression did not significantly affect OS ( $p = 0.111$ ). After adjustment for the other factors by backward stepwise Cox regression analysis, only lymph node status at presentation and tumor stage—but not SLC34A2 IHC expression—were identified as independent factors for OS. Yet, our results showed that patients with tumors expressing high levels of SLC34A2 had significantly shorter DFS ( $p = 0.005$ ). Backward stepwise Cox regression analysis indicated that SLC34A2 IHC expression as well as age and lymph node status at presentation was independent factors affecting the DFS of PTC cases studied herein. This was in agreement with Han et al. [14] whose PTC cases that showed upregulated SLC34A2 gene expression had shorter relapse-free survival. Similarly, SLC34A2 expression has been reported as an independent factor for shorter DFS in CRC and bladder cancer [23]. A possible explanation for the significant effect of SLC34A2 on DFS, but not on OS, could be the fact that it is linked to BRAF mutations, which have been shown to significantly affect the DFS of PTC cases but not their OS. It could also be partly attributed to the fact that PTC patients generally have very long OS [33, 34].

The SLC34A2 gene product is the type II sodium-phosphate cotransporter (NaPi2b), which is highly expressed on the surface of PTC cells. Preclinical studies should be conducted to test the effectiveness of targeting this gene product by antibody–drug conjugates (ADCs) that can deliver cytotoxic agents to cells that express this specific cell marker (NaPi2b) [35]. Thus, anti-NaPi2b ADCs might be a promising therapeutic modality for the treatment of PTC. A recent study associating anti-NaPi2b antibody with BRAF mutations provided a theoretical basis for SLC34A2 inhibition and BRAF inhibition combined therapy which if validated and implemented might provide better management of PTC [14].

A limitation to this study is that the BRAF status of the included cases was not available. Hence, further studies

should be conducted to evaluate the relationship between SLC34A2 and BRAF status in PTC.

In conclusion, to the best of our knowledge, this is the first IHC study to provide evidence that SLC34A2 expression is an independent factor facilitating PTC progression and metastasis. Moreover, it is the first IHC study conducted on a relatively large cohort of PTC patients that showed SLC34A2 expression was increased in PTC samples compared with control samples of normal thyroid tissue and was correlated with clinicopathological indicators of poor prognosis.

## 6. Conclusion

The overall data confirmed that high SLC34A2 IHC expression correlated with adverse clinicopathological prognostic parameters and could serve as an independent factor for DFS. Thus, it could be useful to improve the risk stratification of PTC patients to achieve better management.

## Data Availability

All data generated or analyzed during this study is included in this published article.

## Ethical Approval

All patients who participated in this study signed a written, informed consent. The study was approved by the Research Ethical Committee (REC) at the Faculty of Medicine, Ain Shams University.

## Conflicts of Interest

The authors declare that they have no conflicts of interest/competing interests.

## Authors' Contributions

Sarah Adel Hakim designed, coordinated, reviewed the histological diagnosis, evaluated immunohistochemistry, performed data collection, performed statistical analysis, and drafted the manuscript. Rasha Mohamed Abd El Atti performed data collection, reviewed the histological diagnosis, evaluated immunohistochemistry, and critically reviewed the manuscript. Reham Mohamed Faheim performed data collection and critically reviewed the manuscript. Hoda Hassan Abou Gabal designed, coordinated, reviewed the histological diagnosis, evaluated immunohistochemistry, performed data collection and statistical analysis, carried out photographing, and critically reviewed the manuscript. The authors read and approved the final manuscript.

## References

- [1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," *CA: A Cancer Journal for Clinicians*, vol. 68, no. 6, pp. 394–424, 2018.



- [2] R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2019," *CA: a Cancer Journal for Clinicians*, vol. 69, no. 1, pp. 7–34, 2019.
- [3] M. E. Cabanillas, D. G. McFadden, and C. Durante, "Thyroid cancer," *Lancet*, vol. 388, no. 10061, pp. 2783–2795, 2016.
- [4] F. Galuppini, M. Fassan, L. Bertazza et al., "Programmed cell death 4 (PDCD4) as a novel prognostic marker for papillary thyroid carcinoma," *Cancer Management and Research*, vol. 11, pp. 7845–7855, 2019.
- [5] J. He, M. Zhou, X. Li et al., "SLC34A2 simultaneously promotes papillary thyroid carcinoma growth and invasion through distinct mechanisms," *Oncogene*, vol. 39, no. 13, pp. 2658–2675, 2020.
- [6] M. A. Lacerda-Abreu, T. Russo-Abrahão, R. Q. Monteiro, F. D. Rumjanek, and J. R. Meyer-Fernandes, "Inorganic phosphate transporters in cancer: functions, molecular mechanisms and possible clinical applications," *Biochimica Et Biophysica Acta. Reviews on Cancer*, vol. 1870, no. 2, pp. 291–298, 2018.
- [7] N. Hernando and C. A. Wagner, "Mechanisms and regulation of intestinal phosphate absorption," *Comprehensive Physiology*, vol. 8, no. 3, pp. 1065–1090, 2018.
- [8] H. S. Kim, D. H. Kim, J. Y. Kim et al., "Microarray analysis of papillary thyroid cancers in Korean," *The Korean Journal of Internal Medicine*, vol. 25, no. 4, pp. 399–407, 2010.
- [9] D. Wu, S. Hu, Y. Hou, Y. He, and S. Liu, "Identification of potential novel biomarkers to differentiate malignant thyroid nodules with cytological indeterminate," *BMC Cancer*, vol. 20, no. 1, p. 199, 2020.
- [10] S. M. Hsu, L. Raine, and H. Fanger, "Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures," *The Journal of Histochemistry and Cytochemistry*, vol. 29, no. 4, pp. 577–580, 1981.
- [11] Z. Zhang, S. Ye, M. Zhang et al., "High expression of SLC34A2 is a favorable prognostic marker in lung adenocarcinoma patients," *Tumour Biology*, vol. 39, no. 7, article 101042831772021, 2017.
- [12] J. He, M. Zhou, X. Chen et al., "Inhibition of SALL4 reduces tumorigenicity involving epithelial-mesenchymal transition via Wnt/ $\beta$ -catenin pathway in esophageal squamous cell carcinoma," *Journal of Experimental & Clinical Cancer Research*, vol. 35, no. 1, p. 98, 2016.
- [13] J. He, Y. Jin, M. Zhou et al., "Solute carrier family 35 member F2 is indispensable for papillary thyroid carcinoma progression through activation of transforming growth factor- $\beta$  type I receptor/apoptosis signal-regulating kinase 1/mitogen-activated protein kinase signaling axis," *Cancer Science*, vol. 109, no. 3, pp. 642–655, 2018.
- [14] Y. Han, X. Yu, Y. Yin et al., "Identification of potential BRAF inhibitor joint therapy targets in PTC based on WGCAN and DCGA," *Journal of Cancer*, vol. 12, no. 6, pp. 1779–1791, 2021.
- [15] H. J. Schulten, R. Alotibi, A. al-Ahmadi et al., "Effect of BRAFmutational status on expression profiles in conventional papillary thyroid carcinomas," *BMC Genomics*, vol. 16, Suppl 1, p. S6, 2015.
- [16] L. B. Rangel, C. A. Sherman-Baust, R. P. Wernyj, D. R. Schwartz, K. R. Cho, and P. J. Morin, "Characterization of novel human ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of gene expression," *Oncogene*, vol. 22, no. 46, pp. 7225–7232, 2003.
- [17] D. R. Chen, S. Y. Chien, S. J. Kuo et al., "SLC34A2 as a novel marker for diagnosis and targeted therapy of breast cancer," *Anticancer Research*, vol. 30, no. 10, pp. 4135–4140, 2010.
- [18] G. Ge, C. Zhou, Y. Ren et al., "Enhanced SLC34A2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling," *Tumour Biology*, vol. 37, no. 4, pp. 5049–5062, 2016.
- [19] X. Liu, X. Zhou, H. Xu, Z. He, X. Shi, and S. Wu, "SLC34A2 regulates the proliferation, migration, and invasion of human osteosarcoma cells through PTEN/PI3K/AKT signaling," *DNA and Cell Biology*, vol. 36, no. 9, pp. 775–780, 2017.
- [20] K. E. Fisher, Q. Yin-Goen, D. Alexis et al., "Gene expression profiling of clear cell papillary renal cell carcinoma: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma," *Modern Pathology*, vol. 27, no. 2, pp. 222–230, 2014.
- [21] Y. Wang, W. Yang, Q. Pu et al., "The effects and mechanisms of SLC34A2 in tumorigenesis and progression of human non-small cell lung cancer," *Journal of Biomedical Science*, vol. 22, no. 1, p. 52, 2015.
- [22] L. Liu, Y. Yang, X. Zhou, X. Yan, and Z. Wu, "Solute carrier family 34 member 2 overexpression contributes to tumor growth and poor patient survival in colorectal cancer," *Bio-medicine & Pharmacotherapy*, vol. 99, pp. 645–654, 2018.
- [23] W. Ye, C. Chen, Y. Gao et al., "Overexpression of SLC34A2 is an independent prognostic indicator in bladder cancer and its depletion suppresses tumor growth via decreasing c-Myc expression and transcriptional activity," *Cell Death & Disease*, vol. 8, no. 2, article e2581, 2017.
- [24] L. M. Hurtado-López, A. Ordoñez-Rueda, F. R. Zaldivar-Ramírez, and E. Basurto-Kuba, "Regional node distribution in papillary thyroid cancer with microscopic metastasis," *Journal of Thyroid Research*, vol. 2018, Article ID 1718284, 5 pages, 2018.
- [25] F. Basolo, L. Torregrossa, R. Giannini et al., "Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases," *The Journal of Clinical Endocrinology and Metabolism*, vol. 95, no. 9, pp. 4197–4205, 2010.
- [26] S. L. Oyer, V. A. Smith, and E. J. Lentsch, "Reevaluating the prognostic significance of age in differentiated thyroid cancer," *Otolaryngology and Head and Neck Surgery*, vol. 147, no. 2, pp. 221–226, 2012.
- [27] N. Nilubol, L. Zhang, and E. Kebebew, "Multivariate analysis of the relationship between male sex, disease-specific survival, and features of tumor aggressiveness in thyroid cancer of follicular cell origin," *Thyroid*, vol. 23, no. 6, pp. 695–702, 2013.
- [28] R. H. Grogan, S. P. Kaplan, H. Cao et al., "A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up," *Surgery*, vol. 154, no. 6, pp. 1436–1447, 2013.
- [29] K. Matsuzu, K. Sugino, K. Masudo et al., "Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases," *World Journal of Surgery*, vol. 38, no. 1, pp. 68–79, 2014.
- [30] K. Guo and Z. Wang, "Risk factors influencing the recurrence of papillary thyroid carcinoma: a systematic review and meta-analysis," *International Journal of Clinical and Experimental Pathology*, vol. 7, no. 9, pp. 5393–5403, 2014.
- [31] C. Liu, T. Chen, W. Zeng et al., "Reevaluating the prognostic significance of male gender for papillary thyroid carcinoma and microcarcinoma: a SEER database analysis," *Scientific Reports*, vol. 7, no. 1, p. 11412, 2017.
- [32] J. Jonklaas, G. Noguera-Gonzalez, M. Munsell et al., "The impact of age and gender on papillary thyroid cancer survival,"

*The Journal of Clinical Endocrinology and Metabolism*, vol. 97, no. 6, pp. E878–E887, 2012.

- [33] Y. Ito, A. Miyauchi, M. Kihara, M. Fukushima, T. Higashiyama, and A. Miya, “Overall survival of papillary thyroid carcinoma patients: a single-institution long-term follow-up of 5897 patients,” *World Journal of Surgery*, vol. 42, no. 3, pp. 615–622, 2018.
- [34] H. G. Vuong, U. N. Duong, A. M. Altibi et al., “A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma,” *Endocrine Connections*, vol. 6, no. 3, pp. R8–R17, 2017.
- [35] K. Lin, B. Rubinfeld, C. Zhang et al., “Preclinical development of an anti-NaPi2b (SLC34A2) antibody-drug conjugate as a therapeutic for non-small cell lung and ovarian cancers,” *Clinical Cancer Research*, vol. 21, no. 22, pp. 5139–5150, 2015.